Christelle Vincent-Fabert
Centre national de la recherche scientifique
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Christelle Vincent-Fabert.
Journal of Experimental Medicine | 2013
Pauline Rouaud; Christelle Vincent-Fabert; Alexis Saintamand; Rémi Fiancette; Marie Marquet; Isabelle Robert; Bernardo Reina-San-Martin; Eric Pinaud; Michel Cogné; Yves Denizot
Somatic hypermutation in variable heavy chain rearranged regions is abrogated in the absence of the 3′ regulatory region enhancer, whereas transcription rate in the Ig heavy chain is only partially reduced.
Journal of Immunology | 2009
Christelle Vincent-Fabert; Véronique Truffinet; Rémi Fiancette; Nadine Cogné; Michel Cogné; Yves Denizot
Several studies have reported that regulatory elements located 3′ of the IgH locus (namely hs3a, hs1,2, hs3b, and hs4) might play a role during class switch recombination (CSR) and Ig synthesis. While individual deletion of hs3a or hs1,2 had no effect, pairwise deletion of hs3b (an inverted copy of hs3a) and hs4 markedly affected CSR and Ig expression. Among these two elements, hs4 was tentatively presented with the master role due to its unique status within the 3′ regulatory region: distal position outside repeated regions, early activation in pre-B cells, strong activity throughout B cell ontogeny. To clarify its role, we generated mice with a clean deletion of the hs4 after replacement with a floxed neoR cassette. Surprisingly, and as for previous deletion of hs3a or hs1,2, deletion of hs4 did not affect either in vivo CSR or the secretion level of any Ig isotype. In vitro CSR and Ig secretion in response to LPS and cytokines was not affected either. The only noticeable effects of the hs4 deletion were a decrease in the number of B splenocytes and a decreased membrane IgM expression. In conclusion, while dispensable for CSR and Ig transcription in plasma cells, hs4 mostly appears to contribute to Ig transcription in resting B lymphocytes.
Journal of Oncology | 2011
Rémi Fiancette; Christelle Vincent-Fabert; Estelle Guerin; Franck Trimoreau; Yves Denizot
Some of the most potent inflammatory mediators share a lipid origin. They regulate a wide spectrum of cellular processes including cell proliferation and apoptosis. However, the precise roles and ways (if any) in which these compounds impact the growth and apoptosis of leukemic blasts remain incompletely resolved. In spite of this, significant advances have been recently made. Here we briefly review the current knowledge about the production of lipid mediators (prostaglandins, leukotrienes, platelet-activating factor) by leukemic blasts, the enzymatic activities (phospholipase A2, cyclooxygenases, lipoxygenases) involved in their productions and their effects (through specific membrane bound receptors) on the growth, and apoptosis of leukemic blasts.
Journal of Biological Chemistry | 2012
Pauline Rouaud; Christelle Vincent-Fabert; Rémi Fiancette; Michel Cogné; Eric Pinaud; Yves Denizot
Background: We examined the effect of deletion of the heavy chain regulatory region (RR) on VDJ recombination in B-cells. Results: V, D, and J usage is unaffected by the absence of the IgH RR. Conclusion: The IgH RR is dispensable for V(D)J diversity. Significance: This region only orchestrates IgH locus activity during late stages of B-cell differentiation. V(D)J recombination occurs during the antigen-independent early steps of B-cell ontogeny. Multiple IgH cis-regulatory elements control B-cell ontogeny. IGCR1 (intergenic control region 1), the DQ52 promoter/enhancer, and the intronic Emu enhancer, all three located upstream of Cmu, have important roles during V(D)J recombination, whereas there is no clue about a role of the IgH regulatory region (RR) encompassing the four transcriptional enhancers hs3a, hs1,2, hs3b, and hs4 during these early stages. To clarify the role of the RR in V(D)J recombination, we totally deleted it in the mouse genome. Here, we show that V(D)J recombination is unaffected by the complete absence of the IgH RR, highlighting that this region only orchestrates IgH locus activity during the late stages of B-cell differentiation. In contrast, the earliest antigen-independent steps of B-cell ontogeny would be under the control of only the upstream Cmu elements of the locus.
European Journal of Immunology | 2010
Christelle Vincent-Fabert; Rémi Fiancette; Michel Cogné; Eric Pinaud; Yves Denizot
The 3′ regulatory region (3′RR) located downstream of the IgH gene is the master element that controls class switch recombination and sustains high‐level transcription at the plasma‐cell stage. This latter role suggests that the 3′RR may be involved in oncogene deregulation during the frequent IgH translocation events associated with B‐cell malignancies. A convincing demonstration of the essential contribution of 3′RR in lymphomagenesis has been provided by transgenic animal models. The mouse 3′RR shares a strong structural homology with the regulatory regions located downstream of each human Cα gene. Mouse models exploring the role of the 3′RR in B‐cell physiology and in malignancies should provide useful indications about the pathophysiology of human cell lymphocyte proliferation.
Journal of Immunology | 2011
Rémi Fiancette; Pauline Rouaud; Christelle Vincent-Fabert; Brice Laffleur; Virginie Magnone; Michel Cogné; Yves Denizot
Although c-myc is classically described as the driving oncogene in Burkitt’s lymphoma (BL), deregulation and mutations of c-myc have been reported in multiple solid tumors and in other mature B cell malignancies such as mantle cell lymphoma (MCL), myeloma, and plasma cell lymphoma (PCL). After translocation into the IgH locus, c-myc is constitutively expressed under the control of active IgH enhancers. Those located in the IgH 3′ regulatory region (3′RR) are master control elements of class switch recombination and of the transcriptional burst associated with plasma cell differentiation. c-myc-3′RR mice are prone to lymphomas with rather homogeneous, most often BL-like, phenotypes with incomplete penetrance (75% tumor incidence) and long latencies (10–12 mo). To reproduce c-myc–induced mature B cell lymphomagenesis in the context of an additional defect often observed in human lymphomas, we intercrossed c-myc-3′RR with p53+/− mice. Double transgenic c-myc-3′RR/p53+/− mice developed lymphoma with short latency (2–4 mo) and full penetrance (100% tumor incidence). The spectrum of B lymphomas occurring in c-myc-3′RR/p53+/− mice was widened, including nonactivated (CD43−) BL, activated (CD43+) BL, MCL-like lymphoma, and PCL, thus showing that 3′RR-mediated deregulation of c-myc can promote various types of B lymphoproliferation in cells that first acquired a p53 defect. c-myc/p53+/− mice closely reproduce many features of BL, MCL, and PCL and provide a novel and efficient model to dissect the molecular events leading to c-myc–induced lymphomagenesis and an important tool to test potential therapeutic agents on malignant B cells featuring various maturation stages.
Oncotarget | 2017
Nour Ghazzaui; Alexis Saintamand; Hussein Issaoui; Christelle Vincent-Fabert; Yves Denizot
Deregulation and mutations of c-myc have been reported in multiple mature B-cell malignancies such as Burkitt lymphoma, myeloma and plasma cell lymphoma. After translocation into the immunoglobulin heavy chain (IgH) locus, c-myc is constitutively expressed under the control of active IgH cis-regulatory enhancers. Those located in the IgH 3 regulatory region (3RR) are master control elements of transcription. Over the past decade numerous convincing demonstrations of 3RRs contribution to mature c-myc-induced lymphomagenesis have been made using transgenic models with various types of IgH-c-myc translocations and transgenes. This review highlights how IgH 3RR physiological functions play a critical role in c-myc deregulation during lymphomagenesis.
Advances in Immunology | 2011
Eric Pinaud; Marie Marquet; Rémi Fiancette; Sophie Péron; Christelle Vincent-Fabert; Yves Denizot; Michel Cogné
Oncotarget | 2012
Pauline Rouaud; Rémi Fiancette; Christelle Vincent-Fabert; Virginie Magnone; Michel Cogné; Pierre Dubus; Yves Denizot
American Journal of Pathology | 2012
Christelle Vincent-Fabert; Rémi Fiancette; Pauline Rouaud; Christel Baudet; Véronique Truffinet; Virginie Magnone; Angélique Guillaudeau; Michel Cogné; Pierre Dubus; Yves Denizot